Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian Deschuytner; Chief Financial Officer, Chief Operating Officer, Senior Vice President; Mersana ...

I’m part of the Leerink Partners equity research team. Marty Huber, CEO, Mersana: It’s a Jonathan Chang, Equity Research, Leerink Partners: pleasure to host the management team of Mersana.

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

MERSANA THRPEUTIC ($MRSN) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of -$0.11 per share, beating estimates of -$0.16 by $0 ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Mersana Therapeutics has a one year low of $0.46 and a one year high of $6.28. The business’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $1.55.

Date/Time: Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com.

Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.

Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all ...